This database contains 66 studies, archived under the term: "memantine"
Click here to filter this large number of results.
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia
Larsson, Victoria,
Engedal, Knut,
Aarsland, Dag,
Wattmo, Carina,
Minthon, Lennart,
Londos, Elisabet
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias.; Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer’s disease (AD) in domains according to the […]
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece
Förstl, H.,
Stamouli, S. S.,
Janetzky, W.,
Galanopoulos, A.,
Karageorgiou, C.,
Tzanakaki, M.
Background/aims: Results from German and Greek non-interventional studies were compared to investigate possible differences concerning efficacy, tolerability and compliance between both countries.; Methods: In two open-label, multicentre, non-interventional studies, 4,305 patients with mild to severe Alzheimer’s disease (AD) were treated with daily doses of 20 mg memantine for 6 months. Efficacy was assessed using the […]
MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
Ashford, J. W.,
Adamson, M.,
Beale, T.,
La, D.,
Hernandez, B.,
Noda, A.,
Rosen, A.,
O'Hara, R.,
Fairchild, J. K.,
Spielman, D.,
Yesavage, J. A.
Objectives: Magnetic Resonance Spectroscopy (MRS) may provide a precise and reliable assessment of the extent and severity of neural tissue loss caused by various diseases. In particular, the N-Acetyl Aspartate (NAA) and Creatine (Cr) ratio has been found to be an indicator of the degree of neuronal loss in Alzheimer’s disease (AD). Memantine is thought […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT
Jones, Rob,
Sheehan, Bart,
Phillips, Patrick,
Juszczak, Ed,
Adams, Jessica,
Baldwin, Ashley,
Ballard, Clive,
Banerjee, Sube,
Barber, Bob,
Bentham, Peter,
Brown, Richard,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Gray, Richard,
Griffin, Mary,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Johnson, Tony,
Jones, Roy,
Knapp, Martin,
Lindesay, James,
McKeith, Ian,
McShane, Rupert,
Macharouthu, Ajay,
O'Brien, John,
Onions, Caroline,
Passmore, Peter,
Raftery, James,
Ritchie, Craig,
Howard, Rob
Background: Alzheimer’s disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia […]
Akatinol memantine in patients with vascular cognitive disorders
Treatment of cognitive disorders developed in cerebrovascular pathology is an actual medical problem. Of great importance is the timed diagnosis of these changes in the earlier phases of the development of cognitive deficit as well as adequate therapy that can delay and prevent the development of such complication as dementia. Pathogenetic mechanisms of cognitive disorders […]
Efficacy of acatinol memantine in mild cognitive disorder
An open 6 month clinical trial of efficacy of acatinol has been carried out in patients with mild cognitive disorder (MCD). Forty patients received acatinol and 20 patients of comparison group were treated with piracetam. Mean age of patients was 67,7+/-7,2 years. Patient’s state was assessed with a battery of scales, questionnaires and neuropsychological tests. […]